Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Perphenazine for schizophrenia.

B Hartung1, M Wada, G Laux

  • 1Martin-Behaim-Str. 7, Munich, Bavaria, Germany, 81373. benno.hartung@gmx.de

The Cochrane Database of Systematic Reviews
|January 28, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Non-Response to Antidepressants: Risk Factors and Therapeutic Possibilities.

Pharmacopsychiatry·2026
Same author

[(Failed) Intubation during emergency coniotomy by the emergency physician].

Die Anaesthesiologie·2026
Same author

Cannabis in road traffic - a retrospective analysis to identify possible cut-off-values.

Forensic science, medicine, and pathology·2025
Same author

Prospective ECG-gated High-Pitch Photon-Counting CT Angiography: Evaluation of measurement accuracy for aortic annulus sizing in TAVR planning.

European journal of radiology·2024
Same author

Parking behaviour under the influence of alcohol.

International journal of legal medicine·2023
Same author

Steroid Maintenance Therapy after Transplantation-Quo Vadis?: Long-Term Prospective Study of Steroid Withdrawal in Kidney and Heart Transplant Recipients. Am J Transplant 5: 720-728, 2005.

Journal of the American Society of Nephrology : JASN·2023
Same journal

Interventions to prevent or cease electronic cigarette use in children and adolescents.

The Cochrane database of systematic reviews·2026
Same journal

Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS).

The Cochrane database of systematic reviews·2026
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
See all related articles

Perphenazine, an antipsychotic, appears as effective as other drugs for schizophrenia, reducing early withdrawal due to symptom worsening. However, limited data prevents definitive conclusions on its clinical effects and safety.

Area of Science:

  • Psychiatry
  • Pharmacology
  • Clinical Trials

Background:

  • Perphenazine is a phenothiazine antipsychotic with potency comparable to haloperidol.
  • It has a long history of use, particularly in Northern Europe and Japan.

Purpose of the Study:

  • To evaluate the clinical efficacy and safety of perphenazine in treating schizophrenia and schizophrenia-like psychoses.
  • To synthesize evidence from randomized controlled trials comparing perphenazine with other treatments.

Main Methods:

  • Systematic review of randomized controlled trials (RCTs) identified through comprehensive database searches and direct contact with pharmaceutical companies.
  • Data extraction and quality assessment were performed independently by two reviewers.
  • Statistical analysis included relative risk (RR) and weighted mean differences (WMD) with intention-to-treat analysis.

Related Experiment Videos

Main Results:

  • The review included 25 studies with 2478 patients, primarily short-term trials conducted between 1961 and 1993.
  • Perphenazine use was associated with a significant reduction in participants discontinuing treatment due to relapse or symptom exacerbation compared to placebo (RR 0.1, NNT 2).
  • Compared to other antipsychotics, perphenazine demonstrated similar efficacy in terms of global state improvement (RR 1.0), but interpretation was limited by poor reporting and diverse comparators.

Conclusions:

  • Despite over 40 years of randomized trials, incomplete reporting and varied comparator drugs hinder definitive conclusions on perphenazine's efficacy and safety.
  • Perphenazine exhibits comparable effects and adverse events to other pooled antipsychotic drugs.
  • Further high-quality trials are warranted to fully elucidate the properties of this established antipsychotic, given its cost-effectiveness and widespread use.